Mario Nuvolone

Dec 8, 2024 | nature.com | Eriberto Noel Natali |Patrick Meier |Victor Greiff |Mario Nuvolone |Katja Fink

Correction to: npj Vaccines https://doi.org/10.1038/s41541-023-00788-7, published online 20 January 2024In the original version of this Article, the code availability conditions were not clear in the Methods section. The article has now been corrected to clarify that research requests for access to the code need to be approved by the code owners.

Oct 3, 2024 | onlinelibrary.wiley.com | Mario Nuvolone |Giovanni Palladini

In their paper, the authors from the Boston University Amyloidosis Center investigate the factors that can hinder the recovery from organ compromise in light chain (AL) amyloidosis.1 This disease, the prototype of monoclonal gammopathies of clinical significance, arises when a typically small B-cell or plasma cell clone produces patient-specific, unstable, amyloid forming light chains (LCs) that deposit in tissues and lead to organ dysfunction and damage.

Jul 28, 2024 | nature.com | Antonio Chaves-Sanjuan |Melissa Milazzo |Giulia Mazzini |Paola Rognoni |Paolo Milani |Chiara Marabelli | +9 more

AbstractSystemic light chain (LC) amyloidosis (AL) is a disease where organs are damaged by an overload of a misfolded patient-specific antibody-derived LC, secreted by an abnormal B cell clone. The high LC concentration in the blood leads to amyloid deposition at organ sites. Indeed, cryogenic electron microscopy (cryo-EM) has revealed unique amyloid folds for heart-derived fibrils taken from different patients.

Feb 12, 2024 | nature.com | Eriberto Noel Natali |Patrick Meier |Victor Greiff |Mario Nuvolone |Katja Fink

Correction to: npj Vaccines https://doi.org/10.1038/s41541-023-00788-7, published online 20 January 2024In this article, the affiliation details for author Alexander Horst were incorrectly given as Alexander Horst1,2 but should have been Alexander Horst1 and other affiliations are renumbered. The original article has been corrected.

Jan 19, 2024 | nature.com | Patrick Meier |Victor Greiff |Mario Nuvolone |Katja Fink |Eriberto Noel Natali

AbstractDengue virus poses a serious threat to global health and there is no specific therapeutic for it. Broadly neutralizing antibodies recognizing all serotypes may be an effective treatment. High-throughput adaptive immune receptor repertoire sequencing (AIRR-seq) and bioinformatic analysis enable in-depth understanding of the B-cell immune response.